thyroid cancer

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

In the August 20, 2020 edition of Journal of Clinical Oncology, Michael C. Kreissl and colleagues report on the results of subset analysis of the ZETA trial.

PURPOSE:

A post hoc analysis of the ZETA trial, vandetanib in advanced medullary thyroid cancer (MTC) was performed to assess the efficacy and safety of vandetanib in patients with progressive and symptomatic MTC. The primary objective of the analysis was to determine progression-free survival of these patients.

PATIENTS AND METHODS

Eligible patients from the ZETA trial were divided into 4 subgroups: progression and symptoms, symptoms only, progression only, and no progression and no symptoms assessed at baseline. PFS, determined from objective tumor measurements, overall survival, time to worsening of pain (TWP), and objective response rate were evaluated.

331 patients were in the trial, 184 had symptomatic and progressive disease at baseline. In this subgroup, the results were similar in magnitude to those documented in the overall trial for PFS (HR, 0.43; 95% CI, 0.28 – 0.64; P < .0001), OS (HR, 1.08; 95% CI, 0.72 – 1.61; P = .71), and TWP (HR, 0.67; 95% CI, 0.43 – 1.04; P = .07), and the observed adverse events were consistent with the known safety profile of vandetanib. In this subgroup, the overall response rate was 37% in the treatment arm versus 2% in the placebo arm. The authors concluded “vandetanib demonstrated clinical benefit—specifically, increased PFS—in patients with symptomatic and progressive MTC.”

Reference:

Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial

https://ascopubs.org/doi/full/10.1200/JCO.19.02790

en_USEnglish